Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maria Diaz"'
Publikováno v:
Biodrugs
New immuno-oncology therapies are improving cancer treatments beyond the former standard of care, as evidenced by the recent and continuing clinical approvals for immunotherapies in a broad range of indications. However, a majority of patients (parti
Autor:
Matthew C. Coffey, Richard G. Vile, Timothy Kottke, Hardev Pandha, Alan Melcher, Jill Thompson, Kevin J. Harrington, Shane Zaidi, Kevin G. Shim, Christopher Parrish, Liz Ilett, Rosa Maria Diaz, Karishma Rajani
Publikováno v:
Molecular Therapy. 24:166-174
Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical models and in early phase clinical trials. Reovirus has direct oncolytic activity against a variety of tumor types and antitumor activity is directly associ
Autor:
Alan Melcher, Oliver Donnelly, Jill Thompson, Hardev Pandha, Candice Willmon, Matthew C. Coffey, Kevin J. Harrington, Shane Zaidi, Rosa Maria Diaz, Peter Selby, Timothy Kottke, Richard G. Vile, Elizabeth Ilett
Publikováno v:
Molecular Therapy. 22(10):1851-1863
Optimum clinical protocols require systemic delivery of oncolytic viruses in the presence of an intact immune system. We show that preconditioning with immune modulators, or loading virus onto carrier cells ex vivo, enhances virus-mediated antitumor
Autor:
Gerard J. Nuovo, Timothy Kottke, Kevin J. Harrington, Alan Melcher, Debabrata Mukhopadhyay, Peter Selby, Jill Thompson, Richard G. Vile, Jose S. Pulido, Matthew C. Coffey, Rosa Maria Diaz, Hardev Pandha, Elizabeth Ilett, John D. Chester
Publikováno v:
Molecular Therapy. 19(10):1802-1812
We have previously reported that a burst of vascular endothelial growth factor (VEGF) signaling to tumor-associated endothelium induces a proviral state, during which systemically delivered oncolytic reovirus can replicate in endothelium, thereby ind
Autor:
Alan Melcher, Feorillo Galivo, Jill Thompson, Kevin J. Harrington, Steven M. Albelda, Rosa Maria Diaz, Timothy Kottke, Phonphimon Wongthida, Candice Willmon, Richard G. Vile
Publikováno v:
Molecular Therapy. 19(1):140-149
Despite having potent oncolytic activity, in vitro, direct intratumoral injection of oncolytic vesicular stomatitis virus (VSV) into established AE17ova mesothelioma tumors in C57Bl/6 mice had no therapeutic effect. During studies to combine systemic
Autor:
Jill Thompson, Rosa Maria Diaz, Phonphimon Wongthida, Timothy Kottke, Alan Melcher, Feorillo Galivo, Richard G. Vile
Publikováno v:
Molecular Therapy. 19:150-158
We show here, for the first time to our knowledge, that the antitumor therapy of oncolytic vesicular stomatitis virus (VSV) in the B16ova model depends upon signaling through myeloid differentiation primary response gene 88 (MyD88) in host cells. VSV
Autor:
Scott E. Strome, Timothy Kottke, Phonphimon Wongthida, Candice Willmon, Feorillo Galivo, Richard G. Vile, Jose S. Pulido, John D. Chester, Alan Melcher, Kevin J. Harrington, Rosa Maria Diaz, Peter Selby, Karen M. Kaluza, Glen N. Barber, Jill Thompson
Publikováno v:
Molecular Therapy. 16(12):1910-1918
To protect viral particles from neutralization, sequestration, nonspecific adhesion, and mislocalization following systemic delivery, we have previously exploited the natural tumor-homing properties of antigen-specific CD8+ T cells. Thus, OT-I T cell
Autor:
Timothy Kottke, Rosa Maria Diaz, Richard G. Vile, Kevin J. Harrington, Alan Melcher, Geoff Hall, Glen N. Barber, Dragan Jevremovic, Peter Selby, Feorillo Galivo, Jill Thompson, Phonphimon Wongthida, John D. Chester
There are several roadblocks that hinder systemic delivery of oncolytic viruses to the sites of metastatic disease. These include the tumor vasculature, which provides a physical barrier to tumor-specific virus extravasation. Although interleukin-2 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9641f09bad1f86170663d3fe5ba0310
https://europepmc.org/articles/PMC2729455/
https://europepmc.org/articles/PMC2729455/